Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Valerio Therapeutics, a developer of DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a company ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...

Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence ...

LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, ...

The MediLedger Project utilises blockchain technology to tackle counterfeit drugs. The project uses blockchain to track and ...

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

Some counterfeits contain bacteria and have high impurity levels or different chemical structures to Lilly's FDA-approved ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Biocon has entered a partnership with Tabuk for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the ...

The FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.